GlassScriptPhysician profile
Ashley Richards Curtis
NPI 1235338500
$3,850.15
in general payments reported to CMS, 2019-2025
23 companies · $1,615 in 2025
The $1,615 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $233 · 2021: $141 · 2022: $250 · 2023: $245 · 2024: $948 · 2025: $1,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,646 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.67 |
| Education | $161.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $835.22 | 2020-2025 | |
| Galderma Laboratories, L.P. | $503.54 | 2019-2025 | Dysport, Nemluvio |
| Regeneron Healthcare Solutions, INC. | $502.53 | 2022-2025 | Dupixent |
| Abbvie INC. | $394.12 | 2020-2025 | Rinvoq |
| Allergan, INC. | $353.54 | 2019-2022 | |
| Janssen Biotech, INC. | $257.49 | 2025 | Tremfya |
| Lilly USA, LLC | $138.02 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Mayne Pharma Commercial LLC | $124.99 | 2021-2025 | |
| Journey Medical Corporation | $99.25 | 2019-2021 | |
| Incyte Corporation | $95.16 | 2022-2024 | Opzelura |
| Pfizer INC. | $94.28 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $90.46 | 2019-2025 | |
| Ucb, INC. | $76.34 | 2025 | Bimzelx |
| Botanix Sb INC | $63.06 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $55.70 | 2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $41.67 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $30.91 | 2025 | |
| Leo Pharma INC. | $21.99 | 2025 | Anzupgo |
| Fresenius Kabi USA, LLC | $16.31 | 2023 | Idacio |
| Dermavant Sciences, INC. | $16.28 | 2024 | Vtama |
| Almirall LLC | $16.27 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.20 | 2025 | Acthar |
| Organon LLC | $6.82 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.